News

Peapod opens new pickup locations in Mass., R.I.

BY Alaric DeArment

QUINCY, Mass. — Stop & Shop is launching nine new pickup locations in Massachusetts and Rhode Island as part of its partnership with online grocer and sister company Peapod.

The two retailers, owned by Carlisle, Pa.-based Ahold USA, said the new pickup spots would allow shoppers to order groceries online for easy pickup. The stores included are in Braintree, Mass.; Cohasset, Mass.; East Weymouth, Mass.; Harwich, Mass.; Milford, Mass.; North Attleboro, Mass.; Providence, R.I.; Pawtucket, R.I.; and Cranston, R.I.

"We’re very excited about the rapid expansion of our new pickup offering, which is now available in 27 locations in Massachusetts, Rhode Island and Connecticut," Stop & Shop New England Division president Joe Kelley said. "Customers love having the option of shopping any time, anywhere from their laptop or smartphone and then picking up their groceries at a time that fits their schedule. It takes less than five minutes, and they don’t even have to get out of their car."

Ahold USA also owns Giant Food Stores of Carlisle, Pa., and Giant Food of Landover, Md.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA approves topical treatment for cutaneous lymphoma

BY Alaric DeArment

MALVERN, Pa. — The Food and Drug Administration approved a new drug made by Ceptaris Therapeutics for treating a type of lymphoma, the company said Monday.

Ceptaris announced the approval of Valchlor (mechlorethamine) gel for stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma, or CTCL, in patients who have previously received skin-directed therapy. The company said the drug was the only FDA-approved topical formulation of mechlorethamine, commonly known as nitrogen mustard. The drug, a chemotherapy agent, is applied to the skin once per day and dries in place. It was previously approved for intravenous treatment of the condition.

"This is good news for patients and the treatment community," Stanford University School of Medicine dermatology professor Youn Kim said. "We now have the confidence of an FDA-approved product backed by evidence from a well-controlled clinical trial that demonstrated clinically meaningful responses in the majority of patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who have received prior skin-directed therapy."


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Stewart Rahr donates $3 million to Prostate Cancer Foundation

BY Alaric DeArment

NEW YORK — Former Kinray owner Stewart Rahr has made a large donation to an organization looking for a cure for prostate cancer.

Saying the move "stunned the crowd," Rahr announced at a gathering at the Hamptons on New York’s Long Island that he would donate $3 million to the Prostate Cancer Foundation, an initiative run by investor Michael Milken, who was host to the event.

Other attendees included David Koch, Eddie Trump, former New York Gov. David Patterson and others.

Rahr announced a deal to sell New York-based Kinray to Cardinal Health in November 2010 for $1.3 billion, setting aside $100 million to establish the Rahr Foundation for philanthropic causes.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?